What one share of Lenz Therapeutics holds
We are a commercial pharmaceutical company focused on the development and commercialization of innovative therapies to improve vision.
Lenz Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.70 |
|---|---|
| Profit | −$4.12 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$3.74 |
| Cash and investments | $0.77 |
| Book value | $6.98 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$868.10 | $19.62 | −$130.34 | — | — |
| 2021 | — | −$70.96 | $5.76 | −$58.76 | — | — |
| 2022 | — | −$53.40 | $3.48 | −$49.98 | — | −$12.04 |
| 2023 | — | −$35.71 | $0.02 | −$30.84 | — | −$47.08 |
| 2024 | $0.00 | −$2.34 | $0.02 | −$2.81 | — | $7.42 |
| 2025 | $0.66 | −$2.85 | $0.03 | −$2.43 | — | $9.07 |
Common questions about Lenz Therapeutics
How much does one share of Lenz Therapeutics earn?
Over the last 12 months, Lenz Therapeutics lost $4.12 for each share on $0.70 of sales.
Does Lenz Therapeutics pay a dividend?
Lenz Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Lenz Therapeutics’s book value per share?
Lenz Therapeutics’s book value is $6.98 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Lenz Therapeutics have?
Each share of Lenz Therapeutics has $0.77 of cash and investments, as of June 30, 2026.
What is Lenz Therapeutics’s free cash flow per share?
−$3.74 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Lenz Therapeutics bought back shares?
Lenz Therapeutics’s share count rose about 36483% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.